Sofinnova Venture Partners IX, L.P. 4
4 · Entasis Therapeutics Holdings Inc. · Filed Oct 2, 2018
Insider Transaction Report
Form 4
Sofinnova Venture Partners IX, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2018-09-28+359,267→ 359,267 total - Conversion
Series B-1 Tranche B Convertible Preferred Stock
2018-09-28−9,502,249→ 0 total→ Common Stock (458,425 underlying) - Purchase
Common Stock
2018-09-28$15.00/sh+337,724$5,065,860→ 1,180,178 total - Conversion
Common Stock
2018-09-28+458,425→ 842,454 total - Conversion
Series B-1 Tranche A Convertible Preferred Stock
2018-09-28−7,446,904→ 0 total→ Common Stock (359,267 underlying)
Footnotes (3)
- [F1]Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
- [F2]The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein.
- [F3]This number includes an aggregate of 24,762 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018.